It is very crucial to identify if Closed-loop insulin delivery can be a potential replacement for SAP insulin therapy of adolescent T1DM management by comparing the glycemic outcomes and hypoglycemic events to measure the adverse effects of the therapies. This evidence concerns the gene INS and type 1 diabetes mellitus.